Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Bioavailability of XC221 100 mg in Healthy Volunteers
NCT05295121Phase 1Completed
- Sponsor
- Valenta Pharm
- Start
- Feb 2022
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aterixen in influenza, coronavirus disease 2019 (COVID-19) and acute respiratory viral infection (ARVI) (2 arms), sponsored by Valenta Pharm. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve from Time 0 to Last Measurable Concentration and 1 more. Started Feb 2022; status: completed.
02
Drugs
aterixen
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)acute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT05295121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295121.